



## OPEN

SUBJECT AREAS:  
NEUROSCIENCE  
ANIMAL BEHAVIOUR  
PSYCHOLOGYReceived  
10 October 2013Accepted  
8 January 2014Published  
24 January 2014Correspondence and  
requests for materials  
should be addressed to  
A.A.D. (aaron.duke@  
uky.edu)

# Anxiolytic-like effects observed in rats exposed to the elevated zero-maze following treatment with 5-HT<sub>2</sub>/5-HT<sub>3</sub>/5-HT<sub>4</sub> ligands

Rob Bell<sup>1</sup>, Aaron A. Duke<sup>2,3</sup>, Paula E. Gilmore<sup>1</sup>, Deaglan Page<sup>1</sup> & Laurent Bègue<sup>3</sup><sup>1</sup>School of Psychology, Queen's University, Belfast, Northern Ireland, UK, <sup>2</sup>Department of Psychology, University of Kentucky, USA, <sup>3</sup>Department of Psychology, Grenoble-Alpes University, France.

The present study examined the effects of administering selective 5-HT antagonists and agonists to rats tested in the elevated zero-maze (EZM) model of anxiety. The EZM paradigm has advantages over the elevated plus-maze (EPM) paradigm with respect to measuring anxiety, yet has been utilized less frequently. Three experiments were conducted each with a diazepam control (0.25, 0.5 and 0.75 mg/kg). In the first experiment, we administered the 5-HT<sub>2C</sub> antagonist RS 102221 (0.5, 1.0, and 2.0 mg/kg) and 5-HT<sub>2C</sub> agonist MK-212 (0.25, 0.5 and 0.75 mg/kg); in the second experiment, we administered the 5-HT<sub>3</sub> antagonist Y-25130 (0.1, 1.0 and 3.0 mg/kg) and 5-HT<sub>3</sub> agonist SR 57227A (0.1, 1.0 and 3.0 mg/kg), and in the third experiment, we administered the 5-HT<sub>4</sub> antagonist RS 39604 (0.01, 0.1, 1.0 mg/kg) and 5-HT<sub>4</sub> agonist RS 67333 (0.01, 0.1 and 0.5 mg/kg). The administration of 5-HT<sub>2/3/4</sub> subtype antagonists all generated behavioral profiles indicative of anxiolytic-like effects in the EZM, which was apparent from examination of both traditional and ethological measures. While little effect was observed from 5-HT<sub>2</sub> and 5-HT<sub>3</sub> agonists, the 5-HT<sub>4</sub> agonist RS 67333 was found to produce a paradoxical anxiolytic-like effect similar to that produced by the 5-HT<sub>4</sub> antagonist RS 39604. We conclude by discussing the implications of these findings.

Interest in the role of the 5-HT receptors in the control of anxiety first arose when clinical trials revealed an anxiolytic-like effect of the non-selective 5-HT<sub>2</sub> antagonist ritanserin in humans<sup>1</sup>. Since this time a number of preclinical trials have been carried out, the majority of which have employed non-selective ligands. However, an increasing awareness of the complexity of the 5-HT receptor family<sup>2</sup> coupled with a number of equivocal findings for non-selective 5-HT agents has led to great importance being placed upon the need to test the role of specific 5-HT receptor subtypes in regulating anxiety.

Although preliminary studies employing animal models of anxiety have, in general, demonstrated that a reduction in 5-HT neurotransmission plays a role in the effects of novel non-benzodiazepine anxiolytics<sup>3</sup>, equivocal results for the effects of 5-HT subreceptor ligands have been reported, particularly in studies using the elevated plus-maze paradigm (EPM)<sup>4</sup>. Inconsistent behavioral profiling of drugs that modulate the 5-HT system led earlier investigators to query the utility of the EPM paradigm<sup>5</sup>; specifically, the predictive validity of the EPM appears to be limited to benzodiazepine-related compounds<sup>6</sup>.

The elevated zero-maze (EZM) paradigm represents an important improvement over the EPM in that it removes any ambiguity in the interpretation of time spent on the hub of the EPM and permits continuous exploration<sup>7-9</sup>. The present paper will compare data obtained in our laboratory using 5-HT<sub>2</sub>, 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptor ligands tested using the EZM paradigm with the results from other studies that have utilized similar receptor ligands in a variety of preclinical models of anxiety. Specifically, we tested the effects of the 5-HT<sub>2C</sub> antagonist RS-102221, the 5-HT<sub>2C</sub> agonist MK-212, the 5-HT<sub>3</sub> antagonist Y-25130, the novel 5-HT<sub>3</sub> agonist SR 57227A, the selective 5-HT<sub>4</sub> antagonist RS 39604, and the high-affinity 5-HT<sub>4</sub> partial agonist RS 67333.

The roles of 5-HT<sub>2</sub><sup>3</sup>, 5-HT<sub>3</sub><sup>10</sup> and 5-HT<sub>4</sub> receptors<sup>11</sup> have been extensively reviewed in a variety of animal models of anxiety. In addition, comprehensive reviews<sup>4,12-14</sup> have examined, inter alia, strategies for experimental modeling of anxiety, the validity of rodent models of anxiety and discussed the progression of such paradigms.



Table 1 | Correlations between study variables and descriptive statistics for combined experiments

	1	2	3	4	5	6	M	SD
1. Time Open							48.5	32.7
2. Open Entries	0.86***						5.5	3.7
3. Stretch Attend Posture	-0.66***	-0.52**					6.2	3.6
4. Head Dips	0.82***	0.77***	-0.68***				7.8	3.5
5. Risk Assessment	-0.81***	-0.68***	0.80***	-0.73***			25.4	21.3
6. Rearing Duration	0.28	0.29	-0.08	0.26	-0.25		11.5	4.0
7. Rearing Frequency	0.55**	0.54**	-0.29	0.37*	-0.47**	0.69***	7.2	2.1

Notes. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

## Results

Combined descriptive statistics for the study variables including time spent on open arms, open arm entries, head dips, SAP, risk assessment, and rearing duration/frequency are presented in Table 1 along with the correlations between aggregated study variables. Tables 2–4 respectively include the specific results for the three experiments. Finally, Table 5 includes a summary of the direction of statistically significant findings across all three experiments.

**Experiment 1: 5-HT<sub>2</sub> receptor ligands.** Analyses revealed significant variation in SAP, head dips, and risk assessment behaviors across the various doses of diazepam. Conversely, diazepam did not lead to significant variation in time spent on the open arms of the maze, number of entries into the open arms, and duration and frequency of rearing behaviors. Follow-up Mann-Whitney  $U$  tests revealed an increased number of head dips for the highest two doses ( $U = 22.0$ ,  $p < 0.05$ ;  $U = 2.0$ ,  $p < 0.01$ ). All three

doses of diazepam were associated with reductions in SAP ( $U = 8.5$ ,  $p < 0.001$ ;  $U = 16.0$ ,  $p < 0.01$ ;  $U = 5.5$ ,  $p < 0.001$ ) and risk assessment ( $U = 13.0$ ,  $p < 0.01$ ;  $U = 18.0$ ,  $p < 0.05$ ;  $U = 13.0$ ,  $p < 0.01$ ).

RS 102221 dose conditions produced significant variation with respect to time spent on open arms, number of open arm entries, SAP, head dips, and risk assessment. Follow-up post-hoc analyses revealed that all doses of RS 102221 were associated with reduced SAP ( $U = 9.5$ ,  $p < 0.01$ ;  $U = 3.0$ ,  $p < 0.001$ ;  $U = 2.0$ ,  $p < 0.001$ ) while only the highest dose of 2.0 mg/kg was associated with increased time on the open arms ( $U = 22.5$ ,  $p < 0.05$ ), and head dips ( $U = 10$ ,  $p < 0.01$ ). Analyses revealed a significant reduction in risk assessment at both the 1.0 mg/kg ( $U = 17.0$ ,  $p < 0.05$ ) and 2.0 mg/kg ( $U = 13.0$ ,  $p < 0.01$ ) doses.

Significant variation was observed across MK-212 dose conditions for rearing duration and rearing frequency. All doses were linked to decreased rearing duration ( $U = 20.0$ ,  $p < 0.05$ ;  $U = 23.0$ ,  $p < 0.05$ ;  $U = 5.0$ ,  $p < 0.001$ ) with the 0.25 mg/kg and 0.75 mg/kg doses being

Table 2 | Results from Experiment One

Diazepam					
Behavior	Saline Control	0.25 mg/kg	0.5 mg/kg	0.75 mg/kg	H-values
Time Open	27.5 (0–52.8)	55.8 (17.6–74.5)	53.2 (20.4–90.5)	50.9 (35.7–82.5)	5.077
Open Entries	4.0 (0–6.8)	5.0 (1.0–8.5)	3.5 (1.0–5.5)	8.5 (5.5–11.3)	7.797
SAP	11.5 (7.8–14.5)	5.5 (2.8–7.3)***	6.5 (4.8–9.3)**	4.0 (2.8–6.3)***	17.414***
Head Dips	5.5 (3.8–7.0)	7.0 (4.0–11.0)	10.5 (5.3–13.3)*	12.5 (11.0–15.8)**	15.648**
Risk Assessment	50.7 (32.6–67.2)	17.4 (6.4–33.8)**	20.9 (11.9–30.1)*	12.6 (5.9–26.3)**	11.744**
Rearing Duration	13.8 (11.6–23.7)	11.3 (6.0–28.2)	10.3 (4.0–19.4)	10.9 (6.3–17.1)	2.405
Rearing Frequency	8.0 (7.0–8.3)	8.0 (3.0–10.5)	6.5 (3.0–9.5)	6.0 (4.0–7.3)	3.060
RS 102221					
Behavior	Saline Control	0.5 mg/kg	1.0 mg/kg	2.0 mg/kg	H-values
Time Open	27.5 (0–52.8)	0.5 (0–52.8)	35.3 (0–78.0)	57.6 (30.9–92.6)*	8.550*
Open Entries	4.0 (0–6.8)	0 (0–1.0)	2.5 (0–10.3)	6.0 (1.8–9.3)	8.235*
SAP	11.5 (7.8–14.5)	3.5 (1.5–6.3)**	3.0 (1.5–4.3)***	4.0 (1.8–5.3)***	18.638***
Head Dips	5.5 (3.8–7.0)	3.5 (1.5–6.3)	7.0 (3.0–14.8)	14.5 (9.0–17.5)**	14.001**
Risk Assessment	50.7 (32.6–67.2)	46.8 (29.0–54.2)	10.3 (6.5–41.1)*	16.5 (4.5–30.9)**	12.495**
Rearing Duration	13.8 (11.6–23.7)	8.5 (1.7–15.1)	14.1 (6.6–19.8)	11.5 (6.0–20.1)	5.551
Rearing Frequency	8.0 (7.0–8.3)	5.5 (1.5–8.0)	6.5 (4.0–10.0)	6.5 (4.8–9.5)	5.865
MK-212					
Behavior	Saline Control	0.25 mg/kg	0.5 mg/kg	0.75 mg/kg	H-values
Time Open	27.5 (0.0–52.8)	4.9 (0.0–58.1)	9.0 (0.0–28.3)	0.0 (0.0–35.0)	1.584
Open Entries	4.0 (0.0–6.8)	1.0 (0.0–4.0)	0.5 (0.5–3.0)	0.0 (0.0–1.0)	5.105
SAP	11.5 (7.8–14.5)	12.5 (10.0–18.8)	14.0 (5.2–18.2)	8.0 (5.5–9.5)	7.271
Head Dips	5.5 (3.8–7.0)	6.0 (3.5–7.2)	2.5 (0.0–6.0)	3.0 (1.5–4.8)	5.821
Risk Assessment	50.6 (32.6–67.2)	81.6 (45.8–112.0)	51.4 (35.9–75.8)	53.5 (33.9–63.7)	4.873
Rearing Duration	13.8 (11.6–23.7)	10.1 (5.2–13.9)*	8.8 (4.7–16.0)*	6.1 (1.1–10.2)*	12.684**
Rearing Frequency	8.0 (7.0–8.2)	4.5 (2.5–6.5)**	5.5 (0.5–3.0)	3.0 (0.8–6.0)**	13.973**

Notes. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , SAP = Stretched Attend Posture. Data expressed as medians (lower to upper quartiles), H-values based on Kruskal-Wallis, p-values based on Mann-Whitney  $U$  post-hoc comparisons with the control condition. Each dose condition included 10 animals with a total of 100 animals included in the study.



Table 3 | Results from Experiment Two

Diazepam					
Behavior	Saline Control	0.25 mg/kg	0.5 mg/kg	0.75 mg/kg	H-values
Time Open	34.1 (5.0–83.0)	11.0 (0.0–26.3)	80.8 (21.0–114.7)	61.8 (13.5–87.6)	8.679*
Open Entries	4.0 (0.8–8.5)	1.5 (0.0–5.0)	9.5 (1.5–13.2)	6.5 (2.8–10.2)	4.835
SAP	8.5 (4.0–11.2)	7.5 (5.0–10.0)	4.0 (1.8–5.2)*	2.0 (0.8–5.0)*	13.890**
Head Dips	5.5 (2.8–8.2)	3.5 (2.0–5.2)	12.5 (6.5–17.0)*	8.5 (6.0–10.5)	14.109**
Risk Assessment	26.4 (11.0–42.0)	55.2 (36.0–63.6)	10.6 (0.0–17.9)	4.0 (0.0–17.0)**	17.218***
Rearing Duration	11.8 (6.4–27.3)	6.6 (2.9–19.2)	12.8 (8.8–19.9)	6.8 (2.4–18.4)	2.483
Rearing Frequency	7.0 (4.0–8.2)	5.0 (1.0–8.0)	6.5 (4.8–11.0)	5.0 (2.0–13.2)	2.490
Y-25130					
Behavior	Saline Control	0.1 mg/kg	1.0 mg/kg	3.0 mg/kg	H-values
Time Open	34.1 (5.0–83.0)	18.4 (18.2–28.5)	97.5 (83.2–32.8)*	43.0 (16.5–70.6)	13.267**
Open Entries	4.0 (0.8–8.5)	4.0 (2.8–7.2)	7.0 (5.0–12.0)*	7.0 (1.5–9.8)	16.487**
SAP	8.5 (4.0–11.2)	9.5 (8.5–11.0)	4.0 (3.0–5.0)*	7.5 (4.0–11.2)	12.880**
Head Dips	5.5 (2.8–8.2)	4.0 (2.8–7.2)	11.0 (9.0–12.2)*	9.5 (1.0–13.2)	8.745*
Risk Assessment	11.8 (6.4–27.3)	44.6 (24.8–66.0)	8.0 (0.0–12.9)**	14.7 (6.7–29.0)	16.584***
Rearing Duration	26.4 (11.0–42.0)	12.9 (12.2–14.2)	15.0 (11.4–18.2)	19.8 (15.3–23.3)	3.760
Rearing Frequency	7.0 (4.0–8.2)	9.5 (6.8–10.2)	9.0 (7.8–11.0)	8.5 (7.0–12.0)	6.352
SR 57227A					
Behavior	Saline Control	0.1 mg/kg	1.0 mg/kg	3.0 mg/kg	H-values
Time Open	34.1 (5.0–83.0)	65.0 (27.6–101.9)	35.7 (21.4–70.3)	2.3 (0.0–51.8)	8.477*
Open Entries	4.0 (0.8–8.5)	9.0 (3.2–13.5)	8.0 (2.8–9.5)	1.0 (0.0–12.2)	5.668
SAP	8.5 (4.0–11.2)	8.5 (5.5–14.2)	13.0 (9.5–17.2)	10.0 (5.8–14.2)	5.943
Head Dips	5.5 (2.8–8.2)	6.5 (6.0–14.5)	5.0 (2.0–6.0)	2.5 (1.0–4.8)	11.106*
Risk Assessment	11.8 (6.4–27.3)	24.6 (5.4–56.7)	53.2 (44.1–77.8)**	20.8 (15.7–46.2)	9.075*
Rearing Duration	26.4 (11.0–42.0)	12.2 (7.0–18.7)	7.4 (5.0–9.6)	7.1 (3.9–10.3)	5.808
Rearing Frequency	7.0 (4.0–8.2)	7.5 (6.8–9.2)	5.0 (3.8–6.2)	5.5 (3.5–7.0)	8.114*

Notes. \* < 0.05, \*\* < 0.01, \*\*\* < 0.001, SAP = Stretched Attend Posture. Data expressed as medians (lower to upper quartiles), H-values based on Kruskal-Wallis, p-values based on Mann-Whitney U post-hoc comparisons with the control condition. Each dose condition included 10 animals with a total of 100 animals included in the study.

also linked to decreased rearing frequency ( $U = 15.0, p < 0.01$ ;  $U = 2.0, p < 0.001$ ).

**Experiment 2: 5-HT<sub>3</sub> receptor ligands.** Analyses revealed that the highest dose of diazepam (0.75 mg/kg) significantly decreased the duration of risk assessment behavior ( $U = 16.0, p < 0.01$ ). The highest two doses of diazepam (0.5 mg/kg and 0.75 mg/kg) were associated with decreased SAP ( $U = 22.0, p < 0.05$ ;  $U = 17.5, p < 0.05$ ) and the 0.5 mg/kg dose was also associated with increased head dips ( $U = 23.5, p < 0.05$ ).

While no significant differences were observed for the 0.1 mg/kg and 3.0 mg/kg doses of Y-25130, a number of effects were observed for the moderate 1.0 mg/kg dose. Specifically, the 1.0 mg/kg Y-25130 dose was associated with significantly increased time spent in the open arms ( $U = 17.0, p < 0.05$ ) and a greater number of open arm entries ( $U = 17.5, p < 0.05$ ). Additionally, this dose was associated with decreased SAP ( $U = 23.0, p < 0.05$ ), decreased risk assessment ( $U = 16.0, p < 0.01$ ), and increased head dips ( $U = 23.0, p < 0.05$ ).

Mann-Whitney  $U$  analysis revealed that the moderate dose of SR 57227A (1.0 mg/kg) was associated with a significant increase in risk assessment ( $U = 16.0, p < 0.01$ ). No other statistically significant effects were observed across the 0.1 mg/kg and 3.0 mg/kg doses of SR 57227A.

**Experiment 3: 5-HT<sub>4</sub> receptor ligands.** Post-hoc analysis revealed that both the 0.5 and 0.75 mg/kg doses of diazepam significantly increased time spent on open arms ( $U = 11.0, p < 0.01$ ;  $U = 13.0, p < 0.01$ ), number of open arm entries ( $U = 23.5, p < 0.001$ ;  $U = 23.5, p < 0.05$ ), and number of head dips ( $U = 9.0, p < 0.01$ ;  $U = 19.0, p < 0.05$ ), while significantly decreasing duration of risk assessment behavior ( $U = 8.0, p < 0.01$ ;  $U = 18.0, p < 0.05$ ).

Additionally, the 0.75 mg/kg dose was linked to decreased rearing duration ( $U = 21.5, p < 0.05$ ).

Mann-Whitney  $U$  analysis revealed that all doses of RS 39604 were associated with significant increases in time spent on open arms ( $U = 1.0, p < 0.01$ ;  $U = 8.0, p < 0.01$ ;  $U = 6.0, p < 0.01$ ) an increased number of open arm entries ( $U = 14.3, p < 0.01$ ;  $U = 15.0, p < 0.01$ ;  $U = 6.0, p < 0.01$ ), increased head dips ( $U = 5.0, p < 0.01$ ;  $U = 13.5, p < 0.01$ ;  $U = 12.5, p < 0.01$ ), and significantly decreased risk assessment ( $U = 3.0, p < 0.01$ ;  $U = 5.0, p < 0.01$ ;  $U = 5.0, p < 0.01$ ).

Analyses revealed that all doses of RS 67333 were associated with an increased number of open arm entries ( $U = 9.0, p < 0.01$ ;  $U = 23.0, p < 0.05$ ;  $U = 23.5, p < 0.05$ ) and decreased risk assessment duration ( $U = 3.0, p < 0.01$ ;  $U = 6.0, p < 0.01$ ;  $U = 20.5, p < 0.01$ ). Furthermore, both the 0.01 mg/kg and 0.1 mg/kg doses of RS 67333 were linked to increased head dips ( $U = 10.5, p < 0.01$ ;  $U = 12.0, p < 0.01$ ) and time spent on the open arms of the maze ( $U = 13.0, p < 0.01$ ;  $U = 11.0, p < 0.01$ ).

## Discussion

While both the 0.5 and 1.0 mg/kg doses of the 5-HT<sub>2C</sub> antagonist RS 102221 failed to significantly modify spatio-temporal measures in the current experiment, the 2.0 mg/kg dose of this drug significantly increased time spent on the open arms of the EZM. This pattern of effects suggests a possible anxiolytic role for higher doses of RS 102221. Consistent with this interpretation, an ethological measure indicative of reduced anxiety (i.e., head dips) was significantly increased only at the 2.0 mg/kg dose. While one earlier experiment failed to find any anxiolytic effects for the 5-HT<sub>2A/2C</sub> antagonist ketanserin<sup>3</sup>, our outcome is consistent with an earlier report of an anxiolytic-like effect of the 5-HT<sub>2B/2C</sub> antagonist SB 200646A<sup>27</sup> and



Table 4 | Results from Experiment Three

Diazepam					
Behavior	Saline Control	0.25 mg/kg	0.5 mg/kg	0.75 mg/kg	H-values
Time Open	13.5 (0.0–40.8)	39.7 (20.9–53.6)	68.6 (50.1–120.7)**	75.8 (28.6–84.4)**	14.93**
Open Entries	1.0 (0.0–4.2)	4.5 (2.0–7.2)	12.5 (6.8–13.2)***	6.5 (1.8–9.0)*	14.44**
SAP	8.0 (1.0–11.2)	5.0 (3.0–10.0)	2.0 (0.8–4.0)	1.0 (0.0–3.8)*	9.01*
Head Dips	3.0 (2.8–5.8)	9.0 (3.0–12.2)	11.0 (7.0–15.8)**	10.5 (4.8–12.5)*	11.08*
Risk Assessment	52.2 (33.8–83.6)	22.6 (13.6–53.8)	8.8 (0.4–23.7)***	4.6 (0.0–43.8)*	13.15**
Rearing Duration	15.6 (5.4–29.6)	16.2 (11.2–21.6)	11.2 (5.4–21.4)	4.8 (1.7–9.6)*	8.66*
Rearing Frequency	7.5 (4.0–9.2)	9.5 (7.2–11.0)	8.0 (4.8–10.2)	3.5 (1.8–5.5)	9.51*
RS 39604					
Behavior	Saline Control	0.01 mg/kg	0.1 mg/kg	1.0 mg/kg	H-values
Time Open	13.5 (0.0–40.8)	126.1 (103.8–163.7)**	88.8 (63.5–123.6)**	82.8 (57.8–109.9)**	23.19***
Open Entries	1.0 (0.0–4.2)	14.0 (12.8–17.5)***	7.0 (3.8–9.5)**	10.0 (7.8–12.5)***	26.52***
SAP	8.0 (1.0–11.2)	2.0 (0.0–5.2)	4.0 (3.8–5.0)	4.0 (2.8–6.2)	7.42
Head Dips	3.0 (2.8–5.8)	14.5 (11.0–16.5)***	8.5 (6.8–10.2)**	9.5 (6.0–10.2)**	18.76***
Risk Assessment	52.2 (33.8–83.6)	2.0 (0.0–9.7)**	4.3 (0.0–11.3)**	5.9 (2.3–15.5)**	19.47***
Rearing Duration	15.6 (5.4–29.6)	12.8 (9.2–23.2)	18.7 (8.3–24.2)	18.8 (11.7–22.5)	0.56
Rearing Frequency	7.5 (4.0–9.2)	10.0 (5.5–15.5)	9.0 (7.0–11.2)	11.0 (9.5–14.2)	6.61
RS 67333					
Behavior	Saline Control	0.01 mg/kg	0.1 mg/kg	0.5 mg/kg	H-values
Time Open	13.5 (0.0–40.8)	79.8 (41.0–103.2)**	82.2 (40.0–100.6)**	53.6 (21.0–83.8)	12.58**
Open Entries	1.0 (0.0–4.2)	10.0 (7.8–14.5)**	6.5 (2.0–10.2)*	5.5 (3.2–9.5)*	13.11**
SAP	8.0 (1.0–11.2)	2.0 (1.8–3.2)	3.5 (2.8–4.2)	8.0 (3.8–10.5)	8.88
Head Dips	3.0 (2.8–5.8)	10.5 (9.2–12.5)**	9.0 (7.8–11.2)**	8.0 (6.0–11.0)	12.48**
Risk Assessment	52.2 (33.8–83.6)	0.4 (0.0–0.6)*	9.2 (3.3–15.1)*	27.2 (13.7–38.1)*	23.57***
Rearing Duration	15.6 (5.4–29.6)	12.4 (5.4–17.2)	5.0 (2.9–13.6)	12.4 (8.8–17.3)	5.43
Rearing Frequency	7.5 (4.0–9.2)	12.0 (6.0–15.0)	8.5 (5.2–11.2)	7.5 (5.8–9.8)	2.66

Notes. \* < 0.05, \*\* < 0.01, \*\*\* < 0.001, SAP = Stretched Attend Posture. Data expressed as medians (lower to upper quartiles), H-values based on Kruskal-Wallis, p-values based on Mann-Whitney U post-hoc comparisons with the control condition. Each dose condition included 10 animals with a total of 100 animals included in the study.

other reports of anxiolytic-like action of 5-HT<sub>2C</sub> blockade in animal models of anxiety<sup>28</sup>.

An examination of traditional measures of anxiety revealed a general lack of effect for the selective 5-HT<sub>2C</sub> agonist MK-212. However, MK-212 was found to significantly reduce the duration of rearing at all doses and to significantly reduce the frequency of rearing at both the lowest and highest doses tested. Factor analysis has found rearing to load on a 'motor activity' factor in the EPM<sup>29</sup> suggesting the possibility that the general lack of effects observed after MK-212 administration may have been due to behavioral inhibition/sedation. Overall, these findings are in agreement with a number of previous studies which also report a general lack of effect of 5-HT<sub>2</sub> agonism in animal models of anxiety<sup>3,30,31</sup>.

The finding that the 1.0 mg/kg dose of Y-25130 increased both time spent on the open arms and total arm entries is in agreement with previous studies examining the effects of 5-HT<sub>3</sub> antagonism on traditional measures in both the EPM and EZM<sup>32,33</sup> and is compatible with an anxiolytic-like profile comparable to that obtained with diazepam. Consistent evidence for this interpretation was also observed from ethological measures with the 1.0 mg/kg dose leading to decreased SAP and risk assessment in conjunction with increased head dips. This latter finding is also in agreement with previous studies including work with the EPM<sup>34</sup>, social interaction test<sup>35</sup>, and light-dark test<sup>17</sup>, in suggesting an anxiolytic effect of 5-HT<sub>3</sub> antagonists in animals. However, it should be noted that these effects were not observed for the smaller (0.1 mg/kg) and larger (3.0 mg/kg) doses suggesting the possibility of a hormetic dose-response curve.

While the 5-HT<sub>3</sub> agonist SR 57227A was found to significantly modify most anxiety-related behaviors as measured in the EZM, examination of the effects of specific doses revealed a general lack

of significant effects when compared to the saline control condition. The 0.1 mg/kg dose of this drug failed to modify any behavioral measures, although the general pattern of results, which include non-significant increases in behavior associated with both anxiogenesis and anxiolysis, would suggest non-specific effects.

The 5-HT<sub>4</sub> antagonist RS 39604 significantly increased both time spent on the open arms and total arm entries in a manner consistent with anxiolysis. These findings are in agreement with those of Silvestre and colleagues<sup>11</sup> as well as Kennett and colleagues<sup>28,36</sup> who previously reported an anxiolytic-like effect of the 5-HT<sub>4</sub> antagonists GR 113808, SB 204070, SB 204070A, and SB 207266A on traditional measures in the EPM. With respect to ethological measures, RS 39604 was found to increase head dips and reduce risk assessment, but failed to modify SAP. Overall, RS 39604 was found to modify less anxiety-related behaviors than diazepam in the current experiment. This finding is again in agreement with the work of Silvestre et al.<sup>11</sup> and Kennett et al.<sup>28,36</sup>, both of whom reported that the effects of 5-HT<sub>4</sub> antagonists were smaller than those of either diazepam or chlordiazepoxide in the EPM, leading both authors to conclude that 5-HT<sub>4</sub> antagonists have modest anxiolytic-like activity when compared with the benzodiazepines.

The 5-HT<sub>4</sub> agonist RS 67333 was found to increase both time on the open arm of the EZM and to increase the number of entries onto open arms, a profile consistent with anxiolysis. This interpretation is further supported by ethological measures (i.e., all doses resulted in a reduction in risk assessment with the 0.01 mg/kg and 0.1 mg/kg doses were associated with an increase in head dips). While this finding is in agreement with previous findings in suggesting that 5-HT<sub>4</sub> agonism is associated with a decrease in anxiety-induced behavioral inhibition<sup>37</sup>, the result is surprising in light of the finding that



Table 5 | Summary of significant findings across three experimental studies relative to saline controls

Drug	Dose (mg/kg)	Open Arms		SAP	Head Dips	Risk Assessment	Rearing	
		Time	Entries				Duration	Frequency
<b>Experiment One</b>								
Diazepam	0.25	-	-	↓	-	↓	-	-
Diazepam	0.50	-	-	↓	↑	↓	-	-
Diazepam	0.75	-	-	↓	↑	↓	-	-
RS 102221	0.50	-	-	↓	-	-	-	-
RS 102221	1.0	-	-	↓	-	↓	-	-
RS 102221	2.0	↑	-	↓	↑	↓	-	-
MK-212	0.25	-	-	-	-	-	↓	↓
MK-212	0.50	-	-	-	-	-	↓	-
MK-212	0.75	-	-	-	-	-	↓	↓
<b>Experiment Two</b>								
Diazepam	0.25	-	-	-	-	-	-	-
Diazepam	0.50	-	-	↓	↑	-	-	-
Diazepam	0.75	-	-	↓	-	↓	-	-
Y-25130	0.1	-	-	-	-	-	-	-
Y-25130	1.0	↑	↑	↓	↑	↓	-	-
Y-25130	3.0	-	-	-	-	-	-	-
SR57227A	0.1	-	-	-	-	-	-	-
SR57227A	1.0	-	-	-	-	↑	-	-
SR57227A	3.0	-	-	-	-	-	-	-
<b>Experiment Three</b>								
Diazepam	0.25	-	-	-	-	-	-	-
Diazepam	0.50	↑	-	-	↑	↓	-	-
Diazepam	0.75	↑	-	↓	↑	↓	↓	-
RS 39604	0.01	↑	↑	-	↑	↓	-	-
RS 39604	0.1	↑	↑	-	↑	↓	-	-
RS 39604	1.0	↑	↑	-	↑	↓	-	-
RS 67333	0.01	↑	↑	-	↑	↓	-	-
RS 67333	0.1	↑	↑	-	↑	↓	-	-
RS 67333	0.5	-	↑	-	-	↓	-	-

Notes. SAP = Stretched Attend Posture, ↑ = increased behaviour (compared to saline control) as detected by Mann-Whitney *U* when Kruskal Wallis *H*-value < 0.05, ↓ = decreased behaviour (compared to saline control) as detected by Mann-Whitney *U* when Kruskal Wallis *H*-value < 0.05.

5-HT<sub>4</sub> antagonism led to a similar anxiolytic profile. One possible explanation for this seeming paradox is a non-rectilinear relation between 5-HT<sub>4</sub> activity and anxiety. An inverted-U shaped anxiolytic profile would be sensitive to 5-HT<sub>4</sub> disruptions whether they were in the form of increased or decreased 5-HT<sub>4</sub> activation. However, further research will be necessary to develop this possibility.

In conclusion, results from this study indicate a potential role for 5-HT<sub>2</sub>, and 5-HT<sub>3</sub> antagonists and an apparently paradoxical role for both 5-HT<sub>4</sub> agonists and 5-HT<sub>4</sub> antagonists in producing anxiolytic-like effects on rats tested in the EZM paradigm. Such results from the use of the EZM can be compared to data from the EPM that is considered comparable following diazepam challenge, although the more direct measure of time spent in the open may represent an advantage of the elevated zero-maze<sup>7</sup>.

The results for the 5-HT<sub>2</sub>, 5-HT<sub>3</sub> and 5-HT<sub>4</sub> antagonists employed in our experiments are consistent with the original hypothesis for the role of serotonin in the pathogenesis of anxiety that was predicated on an association between a reduction in 5-HT turnover and the anxiolytic effects of benzodiazepines suggesting that a reduction of 5-HT neurotransmission results in an anxiolytic-like effect, whereas increased activity produces an anxiogenic-like effect<sup>38</sup>. Notwithstanding this conclusion, the behavioral pharmacology of 5-HT receptor ligands is often more inconsistent than the effects of standard anxiolytics and not all results are explainable in terms of the classic hypothesis, as evinced in our third experiment that demonstrated an anxiolytic-like effect with a compound that increased serotonergic activity.

Moreover, it should be noted standard anxiolytics (e.g., diazepam) sometimes produce counter-intuitive results as well such as the finding in Experiment 2 (see Table 3) that the low dose of diazepam was

associated with less time spent on the open arms of the EZM than the saline control condition. Given that data for these groups were collected over a time span of 18 months, we postulated that such variations may, in part, be due to circadian rhythm effects. Benzodiazepines, such as diazepam, are thought to act by potentiating the action of the neurotransmitter  $\gamma$ -aminobutyric acid, which in turn, has been linked to regulation of the sleep-wake cycle<sup>39</sup>. Hence, the variations in responses to diazepam may be the result of the benzodiazepine acting at varying levels of GABA that mediate the generation of circadian rhythms.

A dual role for 5-HT in the mediation of different types of fear has been posited by Graeff and Zangrossi<sup>40</sup>. Specifically, serotonin may either enhance or reduce anxiety-like behavior depending upon the receptor subtype involved. Indeed, the fact that selective serotonin reuptake inhibitors are efficacious in the treatment of generalized anxiety disorder and in panic disorder indicates that there are conditions in which increased 5-HT activity can reduce anxiety.

## Methods

**Animals.** All work was licensed by the Home Office via the Northern Ireland Department of Health, Social Services and Public Safety in accordance with the UK Animals (Scientific Procedures) Act 1986 and was in full compliance with Queen's University Belfast's Policy on the Use of Animals in Research and Teaching. In each of the three experiments, one hundred male Sprague-Dawley rats were randomly assigned as follows: saline control ( $n = 10$ ), diazepam ( $n = 30$ ), 5-HT antagonist ( $n = 30$ ), and 5-HT agonist ( $n = 30$ ). Animals were supplied from a breeding stock at Queen's University and weighing between 280 and 350 grams were group-housed (5 per cage; cage size 51 × 39 × 19 cm) in a temperature-controlled environment 22 ± 1 °C under a 12-hour reverse light-dark cycle (lights off at 0800 hours) for four weeks prior to testing and prior to experimentation has been handled only for routine husbandry. Food and water were available ad libitum. All animals were both drug and experimentally naive.



**Apparatus.** The design of the maze employed was based on that originally proposed by Shepherd et al.<sup>9</sup> and consists of a black Perspex annular platform, 105 cm in diameter and 10 cm wide, elevated 65 cm above the ground. The maze was divided into four equal quadrants, two of which were enclosed with black Perspex walls, 27 cm in height. The walls were on both the inner and outer sides of the platform so as to provide the 'closed' areas of the maze. The 'open' arms had no walls, but did have a 1 cm lip which acts as a tactile aid to animals when on the open areas of the maze. Lighting was provided by two 60 watt red ceiling lights at a height of 2 m positioned directly over the maze and one 60 watt red bulb positioned closer to the maze. Two cameras poised at 45-degree angles were positioned 1 m above the ground and 1 m from either side of the maze. The cameras were connected to a multiplexer in an adjacent laboratory in order to prevent distractions and provided continuous recording of behavior for subsequent analysis.

**Drugs.** All of the active compounds—MK-212 (0.25–0.75 mg/kg), RS 102221 (0.5–2.0 mg/kg), SR 57227A (0.1–3.0 mg/kg), Y-25130 (0.1–3.0 mg/kg), RS 67333 (0.01–0.5 mg/kg), RS 39604 (0.01–1.0 mg/kg), and the positive comparator, diazepam (0.25–0.75 mg/kg), were obtained from Tocrais Cookson UK. The dose ranges for the drugs were chosen from the experimental pharmacology literature examining the relation between 5-HT and anxiety<sup>3,4,15–20</sup>. All compounds were prepared as solutions or suspensions in physiological vehicle. Saline alone was administered to control animals and diazepam was used as a positive control. All solutions were freshly prepared on the day of testing and administered intraperitoneally (1 ml/kg) 30 minutes prior to testing.

**Procedure.** All testing was conducted between 0800 and 1400 hours. On the day of testing one animal was selected and transferred in a covered box (to maintain darkness) measuring 32 × 16 × 12.5 cm to a room adjacent to the experimental room. Here a subcutaneous (s.c) injection was administered under red light and the animal was placed in a cage measuring 40.5 × 28 × 12 cm containing only sawdust bedding (i.e., no food and water). The animal remained in this staging cage for 30 minutes in order to allow adequate absorption of drug, after which time the animal was transferred to the experimental room (again in a darkened box) and placed on the zero-maze at a junction between an open and closed arm, facing into the closed area. Each animal was placed on an alternative side of the maze so as to avoid any bias. All testing was conducted under red-light. After 5 minutes, the animal was removed from the maze and the maze was washed using an ethanol/water solution so as to avoid olfactory cues transferring from one experimental session to the next. Once testing was complete, computer-based event recording and ethological analysis software (Hindsight ver. 1.5) was used to register the relevant experimental variables. Videotapes were scored blindly by a highly trained observer (intra-observer reliability > 0.8). Behavioral parameters comprised traditional spatio-temporal, locomotion, maintenance and ethological measures<sup>21–23</sup>, which are outlined below.

**Measures.** *Spatio-temporal measures.* Traditional spatio-temporal measures included (a) time on open arms and (b) frequency of open arm entries. The animal was judged to enter into the open arm area of the maze when all four paws crossed the open arm threshold. After crossing into the open arm area, the animal was allowed to have one paw in the closed area of the maze and still be considered in the open area; however, if two paws crossed the threshold, then they were judged to have re-entered the closed area of the maze<sup>9,24</sup>.

*Ethological measures.* *Stretched Attend Posture* was defined as the frequency with which the animal makes a forward elongation of the head and shoulders followed by a retraction to the original position when the animal is on an open arm<sup>23</sup>. *Head dips* measured the frequency of the animal protruding its head over the ledge of an open arm and down towards the floor<sup>25</sup>. Finally, *Risk Assessment* was scored as the frequency of an animal exiting a closed arm of the maze with forepaws and head only, and investigating the surroundings. Risk assessment was scored independently of stretch attend posture, which often accompanied risk assessment<sup>21</sup>.

*Locomotion and maintenance measures.* *Rearing Frequency* was defined as the number of vertical movements against the side or end of walls of the closed arms of the maze or raising up its hind paws sans support in the open area of the maze<sup>26</sup>. *Rearing Duration* measured the time each animal was engaged in rearing behavior.

**Analysis.** Data for each behavioral element were grouped according to treatment and were initially checked for normality and homogeneity of variance. Levene's tests were statistically significant (i.e. assumptions that distributions were normal or variances were equal had to be rejected); therefore, non-parametric tests were conducted (as opposed to data transformation). Data were analyzed using Kruskal-Wallis nonparametric one-way analysis of variance across treatment groups. Where significant variations in the data were identified, post-hoc Mann-Whitney *U* comparisons with control condition were performed. In all cases, a standard significance level  $\alpha$  was set at  $p = 0.05$ .

1. Ceulemans, D. L. S., Hoppenbrouwers, M. L. J. A., Gelders, Y. G. & Reyntjens, A. J. M. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. *Pharmacopsychiatry* **18**, 303–305 (1985).

2. Mengod, G., Cortés, R., Vilaró, M. T. & Hoyer, D. Distribution of 5-HT receptors in the central nervous system. *Handbook of Behavioral Neuroscience*. Elsevier: New York, 2010. Vol. 21, pp. 123–138.
3. Nic Dhonnchadha, B. Á., Bourin, M. & Hascoët, M. Anxiolytic-like effects of 5-HT<sub>2</sub> ligands on three mouse models of anxiety. *Behav. Brain Res.* **140**, 203–214 (2003).
4. Carobrez, A. P. & Bertoglio, L. J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. *Neurosci. Biobehav. Rev.* **29**, 1193–1205 (2005).
5. Menard, J. & Treit, D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. *Neurosci. Biobehav. Rev.* **23**, 591–613 (1999).
6. Borsini, F., Podhorna, J. & Marazziti, D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? *Psychopharmacology* **163**, 121–141 (2002).
7. Braun, A. A., Skelton, M. R., Vorhees, C. V. & Williams, M. T. Comparison of the elevated plus and elevated zero-mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. *Pharmacol. Biochem. Behav.* **97**, 406–415 (2011).
8. Kulkarni, S. K., Singh, K. & Bishnoi, M. Elevated zero-maze: a paradigm to evaluate antianxiety effects of drugs. *Methods Find. Exp. Clin. Pharmacol.* **29**, 343–348 (2007).
9. Shepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J. & Dourish, C. T. Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. *Psychopharmacology* **116**, 56–64 (1994).
10. Olivier, B., van Wijngaarden, I. & Soudjin, W. 5-HT<sub>3</sub> receptor antagonists and anxiety; a preclinical and clinical review. *Eur. Neuropsychopharm.* **10**, 77–95 (2000).
11. Silvestre, J. S., Fernández, A. G. & Palacios, J. Effects of 5-HT<sub>4</sub> receptor antagonists on rat behavior in the elevated plus-maze test. *Eur. J. Pharmacol.* **309**, 219–222 (1996).
12. Cryan, J. F. & Holmes, A. The ascent of mouse: advances in modeling human depression and anxiety. *Nat. Rev. Drug Discov.* **4**, 775–790 (2005).
13. Kalueff, A. V., Wheaton, M. & Murphy, D. L. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. *Behav. Brain Res.* **179**, 1–18. (2007).
14. Neumann, I. D. et al. Animal models of depression and anxiety: What do they tell us about human condition? *Prog. Neuropsychopharmacol. Biol. Psych.* **35**, 1357–1375 (2011).
15. Eglén, R. M., Bonhaus, D. W., Johnson, L. G., Leung, E. & Clark, R. D. Pharmacological characterization of two novel and potent 5-HT<sub>4</sub> receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. *Br. J. Pharmacol.* **115**, 1387–1392 (1995).
16. Eglén, R. M., Wong, E. H., Dumuis, A. & Bockaert, J. Central 5-HT<sub>4</sub> receptors. *Trends Pharmacol. Sci.* **16**, 391–398 (1995).
17. Fontana, D. J., Wong, E., Kilfoil, T. & Eglén, R. A behavioral analysis of RS 42358-197, a novel 5-HT<sub>3</sub> antagonist, suggests a selective anxiolytic action. *2nd International Symposium on Serotonin: From Cell Biology to Pharmacology and Therapeutics*, Houston, Texas. New York: Springer (1992, September).
18. Nic Dhonnchadha, B. Á., Ripoll, N., Clénet, F., Hascoët, M. & Bourin, M. Implication of 5-HT<sub>2</sub> receptor subtypes in the mechanism of action of antidepressants in the four plates test. *Psychopharmacology* **179**, 418–429 (2005).
19. Poncelet, M. et al. Antidepressant-like effects of SR 57227A, a 5-HT<sub>3</sub> receptor agonist, in rodents. *J. Neural Transm.* **102**, 83–90 (1995).
20. Mello Cruz, A. P. et al. Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze. *Psychopharmacology* **182**, 345–354 (2005).
21. Holmes, A. & Rodgers, R. J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? *Pharmacol. Biochem. Behav.* **60**, 473–488 (1998).
22. Mathiasen, L. S., Mirza, N. R. & Rodgers, R. J. Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and zolpidem on anxiety-like behaviours in laboratory mice. *Pharmacol. Biochem. Behav.* **90**, 19–36 (2008).
23. Rodgers, R. J. & Johnson, N. J. T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. *Pharmacol. Biochem. Behav.* **52**, 297–303 (1995).
24. Matto, V., Harro, J. & Allikmets, L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. *Neuropharmacol.* **36**, 389–396 (1997).
25. Setem, J., Pinheiro, A. P., Motta, V. A., Morato, S. & Cruz, A. P. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. *Pharmacol. Biochem. Behav.* **62**, 515–521 (1999).
26. Silva, R. C. B. & Brandao, M. L. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. *Pharmacol. Biochem. Behav.* **65**, 209–216 (2000).
27. Bill, D. J., Forster, E. A., Grewal, S. S. & Fletcher, A. Functional antagonistic and anxiolytic effects of the 5-HT<sub>2C/2B</sub> receptor antagonist, SB-200646A, in rodents. *Br. J. Pharmacol.* **116**, 217 (1995).
28. Kennett, G. A. et al. SB 242084, a selective and brain penetrant 5-HT<sub>2C</sub> receptor antagonist. *Neuropharmacol.* **36**, 609–620 (1997).
29. Cruz, A. P. M., Frei, F. & Graeff, F. G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. *Pharmacol. Biochem. Behav.* **49**, 171–176 (1994).



30. Davis, M., Cassella, J. V., Wrean, W. H. & Kehne, J. H. Serotonin receptor subtype agonists: differential effects on sensorimotor reactivity measured with acoustic startle. *Science* **209**, 521–523 (1986).
31. Rodgers, R. *et al.* Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparison with 8-OH-DPAT, CGS 12066B, TFMPP, and mCPP. *Behav. Pharmacol.* **3**, 632–634 (1992).
32. Dunn, R. W., Carlezon, W. A. & Corbett, R. Preclinical anxiolytic versus antipsychotic profiles of the 5-HT<sub>3</sub> antagonists ondansetron, zacopride, 3 $\alpha$ -tropanyl-1H-indole-3-carboxylic acid ester, and 1 $\alpha$ H, 3 $\alpha$ , 5 $\alpha$ H-tropan-3-yl-3, 5-dichlorobenzoate. *Drug Develop. Res.* **23**, 289–300 (1991).
33. Grewal, S. S., Shepherd, J. K., Fletcher, A., Bill, D. J. & Dourish, C. T. Effects of serotonergic agents in the zero-maze test of anxiety. *J. Psychopharmacol.* **A19** (1993).
34. Upton, N. & Blackburn, T. Anxiolytic-like activity of the selective 5-HT<sub>3</sub> antagonist, BRL 46470A, in the rat elevated X-maze. *Br. J. Pharmacol.* **102**, 253 (1991).
35. Costall, B. *et al.* Effects of the 5-HT<sub>3</sub> receptor antagonists GR 38032F, ICS 205–930 and BRL 43694 in tests for anxiolytic activity. *Br. J. Pharmacol.* **93**, 475 (1988).
36. Kennett, G. A., Bright, F., Blackburn, T. & Sanger, G. Anxiolytic-like actions of the selective 5-HT<sub>4</sub> receptor antagonists SB 204070A and SB 207266A in rats. *Neuropharmacol.* **36**, 707–712 (1997).
37. Fernández, A. G. *et al.* LAS Z-019, a new centrally acting 5-HT<sub>4</sub> agonist. *XVIII National Meeting of the Spanish Society of Pharmacology*, Alicante, Spain. Abstracts P56 (1994, November 2).
38. Griebel, G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. *Pharmacol. Ther.* **65**, 319–395 (1995).
39. Turek, F. W. & Losee-Olson, S. A benzodiazepine used in the treatment of insomnia phase-shifts the mammalian circadian clock. *Nature* **321**, 167–168 (1986).
40. Graeff, F. G. & Zangrossi, H. The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders. *Cent. Nerv. Syst. Agents Med. Chem.* **10**, 207–217 (2010).

## Acknowledgments

This project was funded by the Research and Development Office of the Department of Health, Social Services and Public Safety in Northern Ireland.

## Author contributions

R.B. designed the experiments; P.G. and D.P. performed behavioral recordings and analyzed categories of behaviors. R.B. prepared the initial draft of the manuscript. A.D. and L.B. revised the manuscript in conjunction with R.B. prepared the tables, and conducted additional statistical analyses. All authors commented and approved the final draft.

## Additional information

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Bell, R., Duke, A.A., Gilmore, P.E., Page, D. & Bègue, L. Anxiolytic-like effects observed in rats exposed to the elevated zero-maze following treatment with 5-HT<sub>2</sub>/5-HT<sub>3</sub>/5-HT<sub>4</sub> ligands. *Sci. Rep.* **4**, 3881; DOI:10.1038/srep03881 (2014).



This work is licensed under a Creative Commons Attribution 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0>